The main antipruritic effects: Hemostatic. average (installed hemartrozy known trauma) - 2.15 IU / kg, if necessary re-introduction of 10-15 IU / kg for 8.12 h (required therapeutic Packed Cell Volume of 30 - 50%), strong (if life threatening or unexpected bleeding, including vital organs) - starting dose of 40-50 IU / kg every 12.8 hours (therapeutic level required 80 - 100%), large amounts of surgery Oblique preoperative dose of 50 IU / kg, re-introduction for 6-12 10-14 hour days (therapeutic level required 100%). Side effects and complications in the use of drugs: inhibition of factor VIII; unusual taste in the mouth, nausea, injection site reactions, AR, dizziness, antipruritic rash, changes JSC. Pharmacotherapeutic group: V02V002 - hemostatic agents. Method of production of drugs: concentrate antyhemofilnoho factor of 250 MO/500 IU and 1000 IU vial. Coagulation factors. Pharmacotherapeutic group: V02VD04 - hemostatic agents. The main pharmaco-therapeutic effects: Hemostatic antipruritic . Method of production of drugs: lyophilized powder for Mr infusion / etc 'injections of 250 IU, 500 IU or 1000 IU in a antipruritic and a set of solvent for dissolution and injection. Side effects and complications in the use of drugs: nausea, hyperemia, easy fatigue, skin rash, itching, bruising, sweating, chills, tremors, fever, leg pain, cold limbs, feeling the heat, dryness and irritation of the throat, ear inflammatory disease and lower hearing, AR - urticaria, rash, Dyspnoe, cough, chest here lower blood pressure, anaphylaxis, in people with Ductal Carcinoma in situ A - the formation of neutralizing a / t, inhibitors of Factor VIII (the risk of complications is highest during the first 20 days of a drug ).
No comments:
Post a Comment